Insmed (INSM) PT Raised to $58 at UBS

Insmed (INSM) PT Raised to $67 at Stifel

Stifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More

Increasing unusual option volume: INSM CRDO FFIE GTHX CIM BNED CAMT

Increasing unusual option volume: INSM CRDO FFIE GTHX CIM BNED CAMT

Insmed (INSM) PT Raised to $68 at Truist Securities

Truist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.

The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More

Insmed (INSM) PT Raised to $54 at Wolfe Research

Wolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.

The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More

Insmed (INSM) PT Raised to $62 at BofA Securities

BofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $62.00 (from $40.00) while maintaining a Buy rating.

The analyst comments "This mornings positive readout for novel DPP-1 inhibitor brenso (see report: our initial takes on the data) represents a... More

Insmed (INSM) PT Raised to $63 at Barclays

Barclays analyst Leon Wang raised the price target on Insmed (NASDAQ: INSM) to $63.00 (from $40.00) while maintaining a Overweight rating.... More

Insmed (INSM) call put ratio 1 call to 1.8 puts as share price up 116%

Insmed (NASDAQ: INSM) 30-day option implied volatility is at 71; compared to its 52-week range of 32 to 308. Call put ratio 1 call to 1.8 puts as share price up 116%.

Insmed (INSM) PT Raised to $60 at Morgan Stanley

Morgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $60.00 (from $43.00) while maintaining a Overweight rating.

The analyst comments "With clear positive results from the ASPEN topline data, questions on the conference call focused more on the potential commercial... More

Goldman Sachs Reiterates Buy Rating on Insmed (INSM)

Goldman Sachs analyst Andrea Tan reiterated a Buy rating and $74.00 price target on Insmed (NASDAQ: INSM).

The analyst comments "INSM announced positive topline ASPEN data in patients with non-CF bronchiectasis where brensocatib treatment resulted in statistically significant and clinically meaningful reductions in the frequency of pulmonary exacerbations (21.1%/19.4% for 10mg/25mg, respectively) along with benefit on various... More

TD Cowen Reiterates Buy Rating on Insmed (INSM)

TD Cowen analyst Ritu Baral reiterated a Buy rating and $45.00 price target on Insmed (NASDAQ: INSM).

The analyst commented, "This AM, INSM released very positive, binary topline data from the Ph3 ASPEN trial of brensocatib in NCFBE. A best case... More

JPMorgan Reiterates Overweight Rating on Insmed (INSM)

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $36.00 price target on Insmed (NASDAQ: INSM)

The analyst comments "This morning Insmeds ASPEN study hit a home run scenario. Both the 10mg and 25mg doses reached statistical significance with p-values less than 0.01... More

Stifel Reiterates Buy Rating on Insmed (INSM)

Stifel analyst Stephen D. Willey reiterated a Buy rating and $35.00 price target on Insmed (NASDAQ: INSM).

The analyst comments "This mornings top-line disclosure of P3 ASPEN data represents, in our opinion, a best-case scenario for INSM shares with top-line data not only supportive of what we (conservatively) believe to represent a $2.5B+ commercial opportunity in NCFBE, but also improving visibility into future label expansion opportunities such as CRSsNP (P2 ongoing) and HS (P2 now likely to initiate). We believe todays disclosure also eliminates all balance sheet and capital structure concerns... More

Evercore ISI Reiterates Outperform Rating on Insmed (INSM)

Evercore ISI analyst Liisa Bayko reiterated an Outperform rating and $42.00 price target on Insmed (NASDAQ: INSM).

The analyst comments "Highly anticipated ASPEN data is the best-case scenario for INSM with both doses of brensocatib reaching the primary & multiple secondary endpoints.... More

Midday movers: Nvidia, Apple and GameStop rise; Tesla, DraftKings fall

(Updated - May 28, 2024 11:41 AM EDT)

Investing.com -- U.S. stock futures edged higher Tuesday, starting the holiday-shortened week on a positive note ahead of the release of more key inflation data.

Here are some of the biggest U.S. stock movers today:

Nvidia (NASDAQ: NVDA) stock rose 5%, with the tech giants stock continuing to gain, with its... More

Morgan Stanley Reiterates Overweight Rating on Insmed (INSM)

Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating and $43.00 price target on Insmed (NASDAQ: INSM).

The analyst comments "Positive topline results from the brensocatib Phase 3 ASPEN study for bronchiectasis are a clear win, unlocking massive value for Insmed. Both 10mg and 25mg doses showed statistically significant 19-21% reductions in annualized rate of pulmonary exacerbations.... More

Insmed (INSM) Reports Positive Topline Results from Landmark ASPEN Study of Brensocatib

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized rate of pulmonary exacerbations... More